The national law firm of Parker Waichman LLP, advocates for victims of defective drugs, has filed a lawsuit in Superior Court of New Jersey, Atlantic County Law Division on behalf of an Indiana woman who suffered femur fractures to her right and left legs after taking the oral bisphosphonate Fosamax. The lawsuit names Merck Sharp & Dohme Corp., Merck & Co., Inc., and other manufacturers as defendants.
The lawsuit states that the plaintiff took Fosamax for a number of years prior to fracturing her left femur in July 2010 and her right femur in October. The complaint alleges that Fosamax caused both breaks. The plaintiff alleges that the defendants failed to warn consumers about the increased risks of femur fractures when using Fosamax, even though they knew about these risks. Further, the plaintiff states that had she been aware of these risks, she would not have used Fosamax.
Fosamax and other oral bisphosphonates are supposed to reduce the risk of bone fractures in patients with osteoporosis and conditions such as Paget’s disease and some cancers, however, the lawsuit alleges the drug may do just the opposite. The suit says that a component of the drug suppresses bone turnover while allowing secondary mineralization, and when used long-term, can cause the bones to become brittle and vulnerable to fracture.
The lawsuit says the defective drug caused the plaintiff to suffer the two femur fractures, severe mental and physical pain and suffering, permanent injuries, emotional distress, economic loss due to medical expenses, and living related expenses due to a new lifestyle.